Legal & General Group Plc Invests $1.93 Million in Intellia Therapeutics, Inc. $NTLA

Legal & General Group Plc bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 114,006 shares of the company’s stock, valued at approximately $1,929,000. Legal & General Group Plc owned approximately 0.08% of Intellia Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter worth $26,000. Comerica Bank raised its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics during the third quarter worth about $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics during the third quarter worth about $33,000. Finally, Fifth Third Bancorp purchased a new position in shares of Intellia Therapeutics in the 1st quarter valued at approximately $38,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $12.74 on Monday. The company has a 50-day moving average price of $12.94 and a 200 day moving average price of $13.41. Intellia Therapeutics, Inc. has a 12-month low of $7.95 and a 12-month high of $28.25. The stock has a market cap of $1.79 billion, a P/E ratio of -3.79 and a beta of 1.82.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same quarter in the prior year, the company posted ($0.98) EPS. The business’s revenue for the quarter was down 46.4% on a year-over-year basis. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.

Insiders Place Their Bets

In other news, EVP J III sold 4,677 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Michael Dube sold 2,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NTLA shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Sanford C. Bernstein upped their price target on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a research note on Wednesday, July 15th. Finally, Wedbush boosted their price objective on Intellia Therapeutics from $12.00 to $17.00 and gave the company a “neutral” rating in a report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $21.15.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.